Cosmetics is key.

At least when you’re dealing with an in-situ disease like lentigo maligna. This retrospective review of 334 patients demonstrates that neoadjuvant topical imiquimod 0.5% for 2-3 months enables much smaller excisions while still achieving a recurrence rate of only 4% with a median time to recurrence of 3 years. | Donigan, JAMA Dermatol 2018